Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Clinical Evidence for Node-Negative Patients

Whether patients have node-negative or node-positive breast cancer, the Breast Recurrence Score test is both prognostic and predictive—providing both important information about the estimated risk of distant recurrence and the likelihood of adjuvant chemotherapy benefit.1-6

Clinical Highlights | TAILORx Trial (Predictive) | NSABP B-20 Study (Predictive)

Node-negative predictive clinical trial results

Only the Oncotype DX Breast Recurrence Score test predicts the likelihood of chemotherapy benefit for pre- and post-menopausal, node-negative patients.2

TAILORx trial

Groundbreaking results in patients with ER+, HER2-, N0 breast cancer seeking a chemotherapy benefit prediction2,7-10

Graphic TAILORx Trial

Image substantial benefit RS 0-25

25%

of patients with a low Recurrence Score® result (0-25) had high clinical risk* and may have been overtreated without the Recurrence Score result

*High clinical risk: Grade 1, >3 cm; Grade 2, >2 cm; Grade 3, >1 cm.
†Assuming that adjuvant chemotherapy would have been recommended because of the high clinical risk.

Image substantial benefit RS 26-100

43%

of patients with a high Recurrence Score result (26-100) had low clinical risk and may have been undertreated without the Recurrence Score result§

†Low clinical risk: Grade 1, ≤3 cm; Grade 2, ≤2 cm; Grade 3, ≤1 cm.
§Assuming that adjuvant chemotherapy would not have been recommended because of the low clinical risk.

Watch Dr. Sharma and Dr. Pusztai talk about TAILORx and what it means for the Oncotype DX Breast Recurrence Score test

Learn more about TAILORx

 

NSABP B-20 study: low Recurrence Score result predicted little to no benefit from chemotherapy

The NSABP B-20 study was performed on a cohort of 651 patients with ER+, node-negative breast cancer from the NSABP B-20 trial. The objective of this study was to determine whether the Recurrence Score result predicted the likelihood of chemotherapy benefit.2

Graph Low Recurrence

Graph High Recurrence

 

NSABP B-20 study: high recurrence Score result predicted large benefit from chemotherapy

Prospective analysis of archived tissue from 651 patients with ER-positive, node-negative, invasive breast cancer treated with tamoxifen or tamoxifen plus CMF/MF. Approximately 45% of the patients were <50 years of age, 2/3 of tumors were ≤2.0 cm in size, and 16% of tumors were progesterone receptor-negative.2

Graph High Recurrence 

Clinical utility in node-positive patients

Icon doctor

Use our online physician portal

Order tests, access results, receive updates, and more in one place.
Sign up now